目的 探討芪藶強心膠囊聯合曲美他嗪治療老年心力衰竭的臨床療效。方法 將咸陽市中心醫(yī)院自2014年1月-2016年1月收治的心力衰竭的老年患者82例作為研究對象，按照患者入院順序分為研究組和對照組各41例，其中對照組患者給予常規(guī)抗心衰的強心、利尿、擴張血管治療措施，同時給予曲美他嗪進行治療，研究組患者在對照組基礎上加用芪藶強心膠囊進行治療，均治療6個月后對比觀察兩組患者的臨床療效、左心室重構指標及N-末端腦鈉肽前體（NT-proBNP）、心肌肌鈣蛋白Ⅰ（cTnⅠ）、超敏C反應蛋白（hs-CRP）等神經內分泌指標。結果 研究組患者臨床總有效率為97.50%，明顯高于曲美他嗪組70.73%，差異具有統計學意義（P<0.05）。治療前兩組患者左心室重構各項指標和神經內分泌各項指標水平比較差異不顯著，經過治療兩組患者左室收縮末期容積（LVESV）、左室舒張末期容積（LVEDV）、左室收縮末期內徑（LVESP）、左室舒張末期內徑（LVEDD）以及NT-proBNP、cTnⅠ和hs-CRP等指標水平均明顯降低，左室射血分數（LVEF）水平則明顯升高，同組治療前后比較差異有統計學意義（P<0.05）；其中研究組患者各項指標改善水平明顯優(yōu)于對照組，差異具有統計學意義（P<0.05）。結論 芪藶強心膠囊聯合曲美他嗪治療老年心力衰竭患者可有效的改善患者的心功能，改善左心室重構的各項指標，降低血清中神經內分泌分泌水平，效果顯著，可推廣使用。

Objective To investigate the effect of Qiliqiangxin capsule combined with QuMei clinical curative effect of trimetazidine in the treatment of senile heart failure. Method From January 2014 to January 2016 will be heart failure admitted in our hospital 82 cases of elderly patients as the research object, according to the order of admission were divided into study group and QuMeitrimetazidine group with 41 cases in each group, the Sibutraminetrimetazidine group were given routine anti heart failure, strong heart diuresis, vasodilator treatment. At the same time give Sibutraminetrimetazidine treatment on the basis of conventional treatment, the patients in the study group based on the use of QuMeitrimetazidine treatment combined with Qiliqiangxin capsule treatment, 6 months after treatment were observed and compared the clinical curative effect of two groups patients. Results The study group of patients with clinical total effective rate was 97.50%, significantly higher than Sibutraminetrimetazidine 70.73%, the difference was statistically significant (P<0.05); before treatment between two groups in patients with left ventricular remodeling index and neuroendocrine indexes level difference is not significant, the level of the three groups of patients LVEDV, LVESV LVESP, LVEDD, and NT-proBNP, cTn I and hs-CRP index were significantly decreased after treatment, the level of LVEF was significantly increased, which indicators to improve the level of patients in the study group was better than the control group, the difference was statistically significant (P<0.05).Conclusion The improvement of heart function in patients with QuMeiQiliqiangxin capsule combined with trimetazidine in the treatment of elderly patients with chronic heart failure can effectively, improve the indexes of left ventricular remodeling, decrease in serum neuroendocrine secretion, obvious effect, could promotion.